Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $0.86 per share a year ago.
Beyond analysts' top-and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Illumina eyes Q4 growth on NovaSeq X momentum, new multiomic launches and stronger sequencing demand despite China export limits.
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.